Iqvia narrows FY25 adjusted EPS view to $11.75-$12.05 from $11.70-$12.10

Consensus $11.83. Narrows FY25 revenue view to $16.1B-$16.3B from $16B-$16.4B, consensus $16.08B. Cuts FY25 adjusted EBITDA view to $3.75B-$3.83B from $3.77B-$3.89B. The company said, “The company is updating its full-year 2025 guidance as follows: revenue between $16,100 million and $16,300 million, Adjusted EBITDA between $3,750 million and $3,825 million, and Adjusted Diluted Earnings per Share between $11.75 and $12.05. This revenue guidance assumes approximately $100 million of COVID-related revenue step-down, entirely in R&DS, approximately 100 basis points of tailwind from foreign exchange, and approximately 150 basis points of contribution from acquisitions.”